INDIANAPOLIS, June 23, 2018 /PRNewswire/ -- Eli Lilly and Company's (NYSE: LLY) ultra rapid lispro (URLi) led to improved and sustained blood sugar control after meals in people with type 1 and type 2 diabetes, according to results from three phase 1b studies evaluating URLi compared to Humalog®. URLi is Lilly's novel mealtime insulin currently in phase 3 development. These data will be presented in three poster presentations at the American Diabetes Association (ADA) 78th Scientific Sessions® in Orlando.
Two of the studies evaluated URLi administered through multiple daily injections in people with type 1 and type 2 diabetes to understand the differences in the pharmacokinetics (the amount of insulin in the blood) and pharmacodynamics (how insulin works to control blood glucose levels) between URLi and Humalog. The third study evaluated URLi delivered through an insulin pump in people with type 1 diabetes. Across all three studies, URLi was absorbed faster than Humalog, which led to improved post-meal blood sugar control that was sustained over time.
Researchers used solid mixed meal tolerance tests (MMTT) to evaluate URLi in people with type 1 and type 2 diabetes, measuring post-meal blood sugar response based on injections 15 minutes before a meal, at the start of the meal, or 15 minutes after the start of a meal. Results showed that compared to Humalog, URLi reduced post-meal blood sugar over the first five hours after eating by 44 percent in people with type 1 diabetes and 105 percent in people with type 2 diabetes when dosed at mealtime. URLi was also evaluated in people with type 1 diabetes using insulin pumps. Results of MMTTs conducted on days 1 and 3 of pump treatment showed that URLi reduced post-meal blood sugar by 20 to 57 percent over the five-hour period after eating.
Overall, URLi and Humalog had similar safety and tolerability profiles across all three studies.
"These data bolster our confidence in ultra rapid lispro as the next advancement for people who require mealtime insulin," said Tom Hardy, senior medical director at Lilly. "Managing diabetes with mealtime insulin can be difficult, often requiring a strict schedule around what and how much people eat, as well as when they take their insulin. URLi has the potential to improve mealtime blood sugar control for people with type 1 and type 2 diabetes."
URLi is currently in phase 3 studies in people with type 1 and type 2 diabetes. These trials are expected to complete later this year.
About the Studies
The pharmacokinetics (PK) and pharmacodynamics (PD) of ultra rapid lispro (URLi) administered by multiple daily injections in people with type 1 and type 2 diabetes were evaluated in two, two-part, randomized, double-blind phase 1b studies. Part A used a 6-period crossover design to evaluate safety and compare postprandial glucose response to solid mixed meal tolerance tests (MMTT) with URLi and Humalog at different injection to mealtime intervals (-15, 0, and +15 minutes). Part B evaluated the safety, PK and PD during two weeks of multiple daily dosing (immediately before a meal) in a parallel design.
The PK and PD of URLi administered through a pump in people with type 1 diabetes were evaluated in a double-blind, randomized cross-over study. The study evaluated 24 adults with type 1 diabetes over three days by administering MMTTs on days 1 and 3 after pump catheter insertion.
Important Safety Information for Humalog
What is the most important information I should know about Humalog?
- Do not share your Humalog KwikPen, Humalog Junior KwikPen, cartridges, reusable pen compatible with Lilly 3 mL cartridges, or syringes with other people, even if the needle has been changed. You may give other people a serious infection or get a serious infection from them.
- Do not change the insulin you use without talking to your healthcare provider. Changes may make you more likely to experience low or high blood sugar. Changes should be made cautiously under the supervision of your healthcare provider.
- Test your blood sugar levels as your healthcare provider instructs.
- Your insulin dose may need to change because of illness, stress, other medicines you take, change in diet, or change in physical activity or exercise.
- When used in a pump, do not mix or dilute Humalog with any other insulin or liquid.
Who should not take Humalog?
- Do not take Humalog if your blood sugar is too low (hypoglycemia) or if you are allergic to insulin lispro or any of the ingredients in Humalog.
Before using Humalog, what should I tell my healthcare providers?
- About all of your medical conditions, including liver, kidney, or heart failure or other heart problems.
- If you are pregnant, planning to become pregnant, or are breastfeeding.
- About all the medicines you take, including prescription (especially ones commonly called TZDs [thiazolidinediones]) and nonprescription medicines, vitamins, and herbal supplements.
How should I use Humalog?
- Humalog is a rapid-acting insulin. Take Humalog within fifteen minutes before eating or right after eating a meal.
- Always make sure you receive the correct type of Humalog from the pharmacy.
- Do not use Humalog if it is cloudy, colored, or has solid particles or clumps in it.
- Inject Humalog under your skin (subcutaneously). Never inject into a vein or muscle. Change (rotate) your injection site with each dose. Make sure you inject the correct insulin and dose.
- Do not re-use needles. Always use a new needle for each injection. Re-use of needles can cause you to receive the wrong dose of Humalog and result in infection.
- Do not drive or operate heavy machinery until you know how Humalog affects you. Do not use alcohol while using Humalog.
What are the possible side effects of Humalog?
- Severe low blood sugar can cause unconsciousness (passing out), seizures, and death. Low blood sugar is the most common side effect. There are many causes of low blood sugar, including taking too much Humalog. It is important to treat it quickly. You can treat mild to moderate low blood sugar by drinking or eating a quick source of sugar right away. Symptoms may be different for each person. Be sure to talk to your healthcare provider about low blood sugar symptoms and treatment.
- Severe life-threatening allergic reactions (whole-body reactions) can happen. Get medical help right away if you develop a rash over your whole body, have trouble breathing, have a fast heartbeat, or are sweating.
- Humalog can cause life-threatening low potassium in your blood (hypokalemia), which can cause severe breathing problems, irregular heartbeat, and death.
- Serious side effects can include swelling of your hands and feet and heart failure when taking certain pills called thiazolidinediones or "TZDs" with Humalog. This may occur in some people even if they have not had heart problems before. Tell your healthcare provider if you have shortness of breath, swelling of your ankles or feet, or sudden weight gain, which may be symptoms of heart failure. Your healthcare provider may need to adjust or stop your treatment with TZDs or Humalog.
- Failure of your insulin pump or infusion set or degradation of the insulin in the pump can cause hyperglycemia and ketoacidosis. Always carry an alternate form of insulin administration in case of pump failure.
- The most common side effects of Humalog include low blood sugar, allergic reactions, including reactions at your injection site, skin thickening or pits at the injection site (lipodystrophy), itching, and rash. These are not all of the possible side effects. Ask your healthcare provider for more information or for medical advice about side effects.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Humalog is available by prescription only.
For additional information, talk to your healthcare providers and please click to access Full Prescribing Information and Patient Prescribing Information.
Please see Instructions for Use included with the Humalog KwikPen.
HI CON ISI 06JUN2017
Approximately 30 million Americans4 and an estimated 425 million adults worldwide have diabetes.5 Type 2 diabetes is the most common type internationally, accounting for an estimated 90 to 95 percent of all diabetes cases in the United States alone.4 Diabetes is a chronic disease that occurs when the body does not properly produce or use the hormone insulin.
About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. Today we are building upon this heritage by working to meet the diverse needs of people with diabetes and those who care for them. Through research, collaboration and quality manufacturing we strive to make life better for people affected by diabetes. We offer a wide range of therapies and a continued determination to provide real solutions—from medicines and technologies to support programs and more. For the latest updates, visit http://www.lillydiabetes.com/ or follow us on Twitter: @LillyDiabetes and Facebook: LillyDiabetesUS.
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and www.lilly.com/newsroom/social-channels.
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Ultra Rapid Lispro as a treatment of type 1 and type 2 diabetes, and Lilly's current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. Among other things, there can be no guarantee that future study results will be consistent with study findings to date, that Ultra Rapid Lispro will receive regulatory approvals or that Ultra Rapid Lispro will prove to be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.
©LillyUSA, LLC 2018. All rights reserved.
Refer to: DeShong Perry-Smitherman; email@example.com
Plum- Möerschel L., Leohr J., et al. Ultra Rapid Lispro (URLi) Reduces Postprandial Glucose Excursions vs. Humalog® in Patients with T1D at Multiple Meal-to-Dose Timing Intervals. Abstract 1010-P. Presented at 78th American Diabetes Association Scientific Sessions; June 22-26, Orlando, FL.
Kapitza C., Leohr J., et al. Ultra Rapid Lispro (URLi) Reduces Postprandial Glucose Excursions vs. Humalog® in Patients with T2D at Multiple Meal-to-Dose Timing Intervals. Abstract 1009-P. Presented at 78th American Diabetes Association Scientific Sessions; June 22-26, Orlando, FL.
Kazda C., Leohr J., et al. Ultra Rapid Lispro (URLi) shows faster absorption of insulin lispro vs Humalog® during insulin pump (CSII) use in patients with T1D. Abstract 1006-P. Presented at 78th American Diabetes Association Scientific Sessions; June 22-26, Orlando, FL.
Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2017. Available at: https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf. November 2017.
International Diabetes Federation. IDF Diabetes Atlas, 8th edn, 2017. Available at: http://www.diabetesatlas.org/. November 2017.
View original content with multimedia:http://www.prnewswire.com/news-releases/new-data-presented-at-the-american-diabetes-association-78th-scientific-sessions-reinforce-potential-of-lillys-ultra-rapid-lispro-in-people-with-type-1-and-type-2-diabetes-300671059.html
SOURCE Eli Lilly and Company